cxcl5  (Bioss)

Journal: Translational Oncology

Article Title: WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells

doi: 10.1016/j.tranon.2026.102680

Figure Lengend Snippet: TNF-α modulates the WISP1 expression in stroma cells of the human bladder. (A) The RT-qPCR determined the expression of WISP1 in the human bladder cells. (B) Two WISP1 isoforms (WISP1v1 and WISP1v2) were found in the human bladder fibroblast (HBdSF) and bladder smooth muscle (HBdSMC) cells by RT-PCR with the pair of primers as shown. The expressions of WISP1, IL-6, CXCL5, CXCL12, and GDF15 of the HBdSF (C) and HBdSMC (D) cells after 10 ng/ml TNF-α treatment assessed by RT-qPCR. WISP1 (E) and IL-6 (F) secretions after TNF-α (0 – 20 ng/mL) treatments in HBdSF cells. Secretion of WISP1 (G) and IL-6 (F) in HBdSMC_shCOL and HBdSMC_shWISP1 cells treated with/without 10 ng/ml of TNF-α. Data are presented as the mean percentage (± SE; n = 4) in relation to the vehicle-treated HBdSMC_shCOL cells. (I) WISP1 secretion after 20 μM CAPE and/or TNF-α in HBdSF cells determined by ELISA assays. Data are presented as the mean percentage (±SE; n = 4) in relation to the vehicle-treated HBdSF cells. (J) The luciferase activity of the WISP1 reporter vector when HBdSMC cells were treated with TNF-α (10 ng/mL) and/or 20 μM CAPE for 24 h. * p < 0.05; ** p < 0.01; ND: no detectable.

Article Snippet: TaqManTM gene expression master mix and polymerase chain reaction (PCR) FAM dye-labeled TaqMan MGB probes for human WISP1 (Hs04234730_m1 for total isoforms and Hs00180245 for WISP1v1), α-SMA (Hs00426835_g1), IL-6 (Hs00985639_m1), GDF15 (Hs00171132_m1), CXCL5 (Hs01099660_g1), SDF-1/CXCL12 (Hs03676656_m1), NDRG1 (Hs00608387_m1), KAI1 (Hs00356310_m1), Maspin (Hs00985283_m1), E-cadherin (Hs01023894_m1), N-cadherin (Hs00169953_m1), Snail (Hs00195591_m1), Slug (Hs00161904_m1), Vimentin (Hs00185584_m1), and β-actin (Hs01060665_g1) were purchased from Thermo Fisher Scientific Inc. (Vilnius, Lithuania).

Techniques: Expressing, Quantitative RT-PCR, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Luciferase, Activity Assay, Plasmid Preparation

Journal: Translational Oncology

Article Title: WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells

doi: 10.1016/j.tranon.2026.102680

Figure Lengend Snippet: WISP1 modulates expressions of α-SMA, IL-6, GDF15, and CXCL5 in bladder stroma cells. The mRNA levels of two WISP1 isoforms (WISP1v1 and WISP1v2) after WISP1 knock-downed in the HBdSF (A) and HBdSMC (B) cells were determined by RT-PCR. The protein levels with quantification analysis of WISP1, GDF15, and α-SMA of HBdSMC (C) and HBdSF (D) cells after mock-knockdown or WISP1-knockdown were assessed by immunoblot assays. The mRNA levels of the WISP1, α-SMA, IL-6, GDF15, and CXCL5 after knockdown of WISP1 in the HBdSMC (E) and HBdSF (F) cells, as indicated, were determined by RT-qPCR. Data are presented as target genes/β-actin of mock-knockdown cells relative to WISP1-knockdown cells. ** p < 0.01.

Article Snippet: TaqManTM gene expression master mix and polymerase chain reaction (PCR) FAM dye-labeled TaqMan MGB probes for human WISP1 (Hs04234730_m1 for total isoforms and Hs00180245 for WISP1v1), α-SMA (Hs00426835_g1), IL-6 (Hs00985639_m1), GDF15 (Hs00171132_m1), CXCL5 (Hs01099660_g1), SDF-1/CXCL12 (Hs03676656_m1), NDRG1 (Hs00608387_m1), KAI1 (Hs00356310_m1), Maspin (Hs00985283_m1), E-cadherin (Hs01023894_m1), N-cadherin (Hs00169953_m1), Snail (Hs00195591_m1), Slug (Hs00161904_m1), Vimentin (Hs00185584_m1), and β-actin (Hs01060665_g1) were purchased from Thermo Fisher Scientific Inc. (Vilnius, Lithuania).

Techniques: Reverse Transcription Polymerase Chain Reaction, Knockdown, Western Blot, Quantitative RT-PCR

Journal: Nature Communications

Article Title: Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177 hi PAD4 hi neutrophils

doi: 10.1038/s41467-025-66897-0

Figure Lengend Snippet: A Differences in RNA-seq between Ctrl and iRFA on day 3 post-iRFA ( n = 3 mice). Volcano plot of DEGs identified by DESeq2, based on a negative binomial model. B Cxcl5 ( P < 0.001) and Il1b ( P = 0.045) in CT26 cells ± OA treated at 37 °C/45 °C via ELISA ( n = 3 biological replicates). ANOVA. C Cxcl5 in CT26 cells treated with DMSO, SB190, or SB580 at 37 °C/45 °C ± OA ( n = 3 biological replicates). P < 0.001, ANOVA. #, P < 0.001 vs . 45 °C + OA + DMSO group. D MPO-dsDNA levels in neutrophils co-cultured with conditioned media from CT26 cells (37 °C/45 °C) ± OA, with Cxcl5 and / or CXCR1/2 inhibitor (Reparixin) treatment ( n = 3 biological replicates). P < 0.001, ANOVA. # vs . 37 °C; ▼ vs . 37 °C + OA; ★ vs . 45 °C; P < 0.001. E (Left) Immunofluorescence in neutrophils co-cultured with 37 °C and 45 °C + OA CT26 / DLD1 TCM supplemented with DMSO / Trametinib (MEK/ERK inhibitor). (Right) cit-H3 + area quantification ( n = 3 biological replicates). P < 0.001, ANOVA. F , Erk and pErk in the neutrophils from iRFA mice. G–I Proteins in neutrophils treated with 37 °C or 45 °C ± OA CT26 TCM supplemented with ± ( G ) Cxcl5, ( H ) SB190, and ( I ) Reparixin. J Lung tissues from the Ctrl and iRFA mice treated with DMSO, Trametinib and/or a P38 inhibitor (Ralimetinib). K HE staining of lung tissues (Circles: lung metastases). L The quantification of lung metastatic area ( n = 9 mice). Ctrl groups: P = 0.059; iRFA groups: P < 0.001; ANOVA. M (Left) Ly6G and cit-H3 immunofluorescence in liver tumors. (Right) Quantification of the cit-H3 + area ( n = 9 mice). P < 0.001, ANOVA. Scale bars, 200 μm. N Ly6G and pErk immunofluorescence in liver tumors. Scale bars, 50 μm. Data are presented as mean values ± SD. C , H SB190: SB202190. C SB580: SB203580. E 37/45: 37 °C/45 °C. E and G – I TCM: conditioned media from tumor cells. Source data are provided as a Source Data file.

Article Snippet: After dewaxing, hydration, and antigen retrieval, the slices were incubated with the following primary antibodies: mCherry (1:200, ab167453, Abcam), Cd45 (1:200, GB11066, Servicebio), CD36 (1:200, 18836-1-AP, Proteintech), FABP4 (1:200, 12802-1-AP, Proteintech), FABP5 (1:200, 12348-1-AP, Proteintech), PPARγ (1:200, 10156-2-AP, Proteintech), p-P38 (1:200, 4511 T, Cell Signaling Technology), and CXCL5 (1:250, bs-2549R, Bioss).

Techniques: RNA Sequencing, Enzyme-linked Immunosorbent Assay, Cell Culture, Immunofluorescence, Staining

Journal: Nature Communications

Article Title: Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177 hi PAD4 hi neutrophils

doi: 10.1038/s41467-025-66897-0

Figure Lengend Snippet: A Treatment timeline for a representative CRLM patient. The patient underwent Dixon surgery following CRLM diagnosis. First tumor evaluation showed a new metastasis in liver S5, and subsequently, RFA was performed. Postoperative PET/CT showed no tumor viability. Intrahepatic S7 metastasis appeared 4 months later. S5 and S7 tissues were obtained through hepatic resection, and pathological examination as well as sequencing were performed. The second progression with new lung metastases occurred at 7 months. Triangles: liver or lung metastases. B Neutrophil infiltration levels in tumors pre- and post-iRFA analyzed by different datasets (Box center line: median; box limits: upper and lower quartiles; whiskers: 1.5× interquartile range). C Representative GSEA analysis of FA metabolism and the PPAR pathway, and the differences in scRNA-seq data between pre- and post-iRFA tumors. Kolmogorov-Smirnov test. FDR correction. D CD36 and CXCL5 staining of the tumors pre- and post-iRFA. E Density quantification of CD36 + and CXCL5 + areas in the tumors pre- and post-iRFA. F CD66b immunofluorescence in tumors pre- and post-iRFA. Scale bars, 50 μm and 10 μm. CD66b + neutrophil counts shown on the left. G MPO and cit-H3 immunofluorescence in tumors pre- and post-iRFA. Scale bars, 50 μm. The cit-H3 + area shown on the left. H Mesenchymal markers, epithelial markers, and CD36 immunofluorescence on CTCs were analyzed. The data represented the proportions of CD36 hi -CTCs, CD36 hi -E-CTCs, and CD36 hi -EM-CTCs in the tumors pre- and post-iRFA. Scale bars, 10 μm. I MPO-dsDNA levels in the peripheral blood pre- and post-iRFA. J The data represented the proportions of CD36 hi -CTCs and CD36 hi -EM-CTCs in the cRFA and iRFA tumors. K MPO-dsDNA levels in the peripheral blood of cRFA and iRFA patients. Data are presented as mean values ± SD; Statistical analysis was performed based on Paired t -test ( B , E , F , and G , n = 8 patients; H and I , n = 13 patients) or Unpaired two-sided t -test ( J , K ); cRFA, n = 5 patients, iRFA, n = 13 patients). Source data are provided as a Source Data file.

Article Snippet: After dewaxing, hydration, and antigen retrieval, the slices were incubated with the following primary antibodies: mCherry (1:200, ab167453, Abcam), Cd45 (1:200, GB11066, Servicebio), CD36 (1:200, 18836-1-AP, Proteintech), FABP4 (1:200, 12802-1-AP, Proteintech), FABP5 (1:200, 12348-1-AP, Proteintech), PPARγ (1:200, 10156-2-AP, Proteintech), p-P38 (1:200, 4511 T, Cell Signaling Technology), and CXCL5 (1:250, bs-2549R, Bioss).

Techniques: Biomarker Discovery, Positron Emission Tomography-Computed Tomography, Sequencing, Staining, Immunofluorescence